ClinicalTrials.gg
RecruitingNCT07247344MAPS-IOUpdated Nov 25, 2025

Multimodal Phenotyping in Adolescent Inpatient Depression: An Observational Study

An observational study in Adolescent, Major Depressive Disorder (MDD and Bipolar Disorder (BD), sponsored by Jiangsu Province Nanjing Brain Hospital. Recruiting at 1 site in China. Open to participants aged 10 Years to 20 Years. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by Jiangsu Province Nanjing Brain Hospital · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
10 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 207 studies in Depressive Disorder, Major with a site in China — 75 open to participants now, 77 under way, 5 of them phase 3. Depressive Disorder, Major · China.

Planned enrollment
5th of 33
1,000 · median 240
Started
2025
with 22 others
Observational
33 of 207
13 open now
Primary completion
2029-03
later than 71 of 76 live
Registered
175th of 207
by date

Among the 207 studies in Depressive Disorder, Major with a site in China, this one is the 5th largest by planned enrollment of the 33 observational ones that give a count, is one of 23 that started in 2025, is one of 33 observational ones, reaches primary completion later than 71 of the 76 other live ones, and was the 175th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

75 of the 207 studies in Depressive Disorder, Major with a site in China are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 10 Years to 20 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Depressive Disorder, Major with a site in China, or all of them as a file.
02

Study summary

This cohort study involves the dynamic collection of clinical information from adolescent patients with major depressive episodes (including both major depressive disorder and bipolar disorder), encompassing serum parameters, physiological-behavioral signals, neuroimaging data, and neuropsychological scales. The study aims to summarize the comprehensive clinical characteristics of this population, identify new risk factors, and establish multivariate predictive models for treatment response, cognitive and emotional impairments. Furthermore, this research will thoroughly investigate the underlying neural mechanisms linking clinical manifestations and neuroimaging features in major depressive episodes.

Read the detailed description

Research Objectives:

  1. To conduct a longitudinal investigation in adolescent patients with major depressive episodes (including major depressive disorder and bipolar disorder) to observe the dynamic progression of cognitive function, emotional disorders, physiological-behavioral characteristics, and related contributing factors.
  2. To systematically explore and summarize the clinical, physiological-behavioral, and neuroimaging characteristics of adolescents with major depressive episodes, with the aim of identifying novel risk factors associated with treatment response and clinical outcomes.
  3. To perform an in-depth investigation into the underlying neurobiological mechanisms of major depressive episodes and examine the interrelationships between clinical manifestations, physiological-behavioral indicators, and neuroimaging outcomes.
  4. To develop a multifactorial predictive model for treatment response and cognitive-emotional impairments in major depressive episodes, integrating clinical, physiological-behavioral, neuroimaging, and biomarker data.
03

Conditions studied

  • Adolescent
  • Major Depressive Disorder (MDD
  • Bipolar Disorder (BD)

Keywords

  • Major Depressive Episode
04

Who can participate

Ages eligible
10 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will recruit participants aged 10-20 years diagnosed with major depressive disorder (MDD) or bipolar disorder (BD) according to DSM-IV criteria. Diagnoses will be confirmed using SCID-I (age ≥18) or K-SADS-PL (age \<18).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 10 and 20 years of age;
  • Diagnosis of major depressive disorder (MDD) or bipolar disorder (BD) according to the , Fourth Edition (DSM-IV). Diagnosis is assessed using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) for participants aged ≥18 years, or the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version (K-SADS-PL) for participants aged \<18 years;
  • Current moderate to severe depressive episode, defined as Hamilton Depression Rating Scale (HAMD) score ≥17;
  • Participants and 1 or 2 parents (patients' age\< 18 years old) provide after the detailed description of the study.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), electroconvulsive therapy (ECT), or standard psychological therapy within 6 months prior to screening;
  • Comorbidity with other Axis I disorders or personality disorders;
  • Judged clinically to be at serious risk of suicide;
  • Diabetes mellitus, hypertension, vascular and infectious diseases and other major medical comorbidities;
  • Unstable medical conditions, e.g., severe asthma; Neurological disorders, e.g., history of head injury with loss of consciousness for ≥ five minutes, cerebrovascular diseases, brain tumors and neurodegenerative diseases;
  • Mental retardation or autism spectrum disorder;
  • to MRI (e.g., severe claustrophobia, pacemakers, metal implants);
  • Current drug or alcohol abuse or dependence;
  • Pregnant or lactating females.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • 1

    The diagnosis of Major Depressive Episode will be made according to the DSM-4 criteria. Neuroimaging assessment will be performed following standardized MRI quality control and interpretation procedures, jointly evaluated by an experienced radiologist and psychiatrist.

    Other: data collection and follow-up

Interventions

  • Otherdata collection and follow-up

    Main measures and data collection methods: 1. Recording of baseline demographic and clinical information of the participants. 2. Multimodal magnetic resonance imaging. 3. Heart rate variability. 4. Electroencephalography. 5. Emotion-related questionnaires. 6. Cognitive tests. 7. Behavioral data collection using wearable devices. 8. Blood samples collection.

06

What researchers measure

Primary outcomes

  1. The 17-item Hamilton Depression Rating Scale (HAMD-17)

    The HAMD-17 scale has 17 items. The total score ranges from 0-52, with higher score indicating more severe depressive symptoms. A total score of 0-7 is considered to be normal. Scores of 17 or higher indicate moderate, severe, or very severe depression.

    Time frame: at baseline, week 1, week 2, week 4, week 24, and up to 1 year

  2. Change in brain functional connectivity measured by resting-state functional MRI

    Resting-state functional magnetic resonance imaging (rs-fMRI) will be employed to evaluate functional connectivity alterations in core brain networks

    Time frame: at baseline, week 1, week 2, week 4, week 24, and up to 1 year

  3. Change in Heart Rate Variability (HRV) via wearable device

    Change in HRV derived from interbeat intervals (IBIs) collected via wearable device.

    Time frame: Within 4 weeks, but not exceeding 1 year.

  4. Change in daily step count and activity patterns recorded via wearable device

    Change in daily step count and overall activity patterns automatically recorded via wearable device.

    Time frame: Within 4 weeks, but not exceeding 1 year.

  5. Change in Cytokines (reported in pg/mL)

    Peripheral blood biomarkers will be measured to evaluate inflammatory and immune responses to treatment. Interferon-α (IFN-α) Interferon-γ (IFN-γ) Interleukin-1β (IL-1β) Interleukin-2 (IL-2) Interleukin-4 (IL-4) Interleukin-5 (IL-5) Interleukin-6 (IL-6) Interleukin-8 (IL-8) Interleukin-10 (IL-10) Interleukin-17 (IL-17) Tumor necrosis factor-alpha (TNF-α)

    Time frame: at baseline, week 1, week 2, week 4, week 24, and up to 1 year

  6. Change in Composite Immune-Inflammatory Ratio Index (unitless)

    This composite index includes platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and monocyte-to-HDL cholesterol ratio (MHR), which together reflect systemic inflammatory activity and immune status.

    Time frame: at baseline, week 1, week 2, week 4, week 24, and up to 1 year

Secondary outcomes

  1. Change in electroencephalographic (EEG) activity measured by resting-state EEG

    EEG recordings will be obtained before and after the treatment to evaluate changes in neural oscillatory activity and functional connectivity, including metrics such as power spectral density (alpha, beta bands), coherence, and event-related potentials.

    Time frame: at baseline, week 1, week 2, week 4, week 24, and up to 1 year

  2. Change from baseline in the Clinical Global Impression-Severity scale (CGI-S)

    The CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. A rating of 1 is considered normal, or with the least severe symptoms, a rating of 7 is extremely ill, or the worst symptoms.

    Time frame: at baseline, week 1, week 2, week 4, week 24, and up to 1 year

  3. Change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS)

    MADRS is a clinician-rated scale used to assess depressive symptom severity and detect changes due to antidepressant treatment. The scale consists of 10 items, each of which is rated from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms). The total score of MADRS ranges from 0 to 60, with higher score indicating more severe depression.

    Time frame: at baseline, week 1, week 2, week 4, week 24, and up to 1 year

  4. The Young Mania Rating Scale (YMRS)

    he Young Mania Rating Scale (YMRS) is an 11-item clinician-rated scale used to assess the severity of manic symptoms. Each item is scored from 0 to 4 or 0 to 8, depending on symptom intensity, with a total score ranging from 0 to 60. Higher scores indicate more severe manic symptoms. A score below 12 is generally considered to reflect remission or minimal symptoms.

    Time frame: at baseline, week 1, week 2, week 4, week 24, and up to 1 year.

  5. Change in Blood Oxygen Saturation

    Change in continuously monitored SpO₂ values from wearable sensors.

    Time frame: Within 4 weeks, but not exceeding 1 year.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2029, 48 months after the start.

Of 121 non-industry observational studies under Depressive Disorder, Major, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 73. This study's planned 48 months is close to that.

Counting every sponsor, half of 150 studies reached it within 38 months; a quarter within 21 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 25, 2025
StartActual
Mar 1, 2025
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07247344
Lead sponsor
Jiangsu Province Nanjing Brain Hospital
Responsible party
Fei Wang (Professor, Jiangsu Province Nanjing Brain Hospital) — Principal investigator
First posted
Nov 25, 2025
Start date
Mar 1, 2025
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Nov 25, 2025

Study contacts

Zexin Lin
Contact
zexinlin@stu.njmu.edu.cn
86-13906900678
Jia Duan
Contact
jia_duan@yeah.net
86-025-83295957
Fei Wang
study chair · the Affiliated Nanjing Brain Hospital, Nanjing Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion